medigraphic.com
Colegio de Medicina Interna de México.

2021, Number 4

<< Back Next >>

Med Int Mex 2021; 37 (4)

Risk factors of hepatocellular carcinoma in patients with chronic hepatitis C virus infection receiving pegylated interferonribavirin treatment

Tobar-Marcillo M, López-Fuentes J

Language: Spanish
References: 16
Page: 469-474
PDF size: 209.98 Kb.


ABSTRACT

Background: Chronic infection with hepatitis C virus (HCV) is one of the main causes of liver cirrhosis and hepatocellular carcinoma.
Objectives: To assess patients receiving treatment with pegylated interferon/ribavirin who had hepatocellular carcinoma and to compare them with patients receiving the same treatment who had not hepatocellular carcinoma.
Materials and Methods: A retrospective, analytical, case-control study was conducted in patients with chronic HCV infection in follow-up in the gastroenterology service at the Regional Hospital Adolfo López Mateos, Mexico City, from 2010, under treatment with pegylated interferon/ribavirin; factors associated with the onset of hepatocellular carcinoma were analyzed.
Results: Thirty-five cases and forty-seven controls were included, the risk factors associated with the development of hepatocellular carcinoma were age, male sex, liver cirrhosis and no sustained viral response. Genotype was not associated with its development.
Conclusions: The risk factors found in the present study do not differ from those reported in the literature; however, it provides important information regarding the treatment and follow-up of Mexican patients with chronic HCV infection.


REFERENCES

  1. Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, et al. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol 2014; 61 (1 Suppl): S79-90. doi. 10.1016/j.jhep.2014.07.010.

  2. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007; 22: S108-11.

  3. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28 (5): 753-770. doi. 10.1016/j.bpg.2014.08.007.

  4. Webster DP, Klenerman P, Dusheiko GM, Hepatitis C. Lancet 2015; 385 (9973): 1124-35. doi. 10.1016/S0140- 6736(14)62401-6.

  5. Singal AK, Singh A, Jaganmohan S, Guturu P, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8 (2): 192-199. doi. 10.1016/j.cgh.2009.10.026.

  6. Chung RT, Baumert TF. Curing chronic hepatitis C–the arc of a medical triumph. N Engl J Med 2014; 370 (17): 1576-8. doi. 10.1056/NEJMp1400986.

  7. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: A systematic review. JAMA 2014; 312: 631-640. doi. 10.1001/jama.2014.7085.

  8. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420.

  9. Chernyak V, Fowler KJ, Kamaya A, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: Imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018; 289 (3): 816-830. doi. 10.1148/radiol.2018181494.

  10. Bruno S, Crosignani A, Maisonneuve P, Rossi S, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-1356. doi. 10.1002/hep.21826.

  11. Lee MH, Yang HI, Yuan Y, L’Italien G, et al. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014; 20 (28): 9270-9280. doi. 10.3748/ wjg.v20.i28.9270.

  12. Sarbah SA, Gramlich T, Younoszai A, Osmack P, et al. Risk factors for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2004; 49 (5): 850-853. doi. 10.1023/b:d das.0000030098.75759.32.

  13. Taura N, Fukuda S, Ichikawa T, Miyaaki H, et al. Relationship of α-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Exp Ther Med 2012; 4 (6): 972-976. doi. 10.3892/etm.2012.709.

  14. Chang KC, Hung CH, Lu SN, Wang JH, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother 2012; 67: 2766-2772. doi. 10.1093/ jac/dks269.

  15. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med 1999; 131: 174-181. doi. 10.7326/0003-4819-131-3-199908030-00003.

  16. Wong A, Le A, Lee MH, Lin YJ, et al. Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. Sci Rep 2018; 8 (1): 7164. doi. 10.1038/s41598-018-25533-2.




2020     |     www.medigraphic.com